Overview
AXGN market data
Price History
AXGN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.34 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.15 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -13.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $13.64 – $49.90 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $2.7B · P/B 11.72 · P/S 10.63.
Company News
Canaccord Genuity Maintains Buy on Axogen, Raises Price Target to $55Benzinga · Jul 30, 2026, 3:38 PM
Citizens Maintains Market Outperform on Axogen, Raises Price Target to $55Benzinga · Jul 30, 2026, 2:01 PM
HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $53Benzinga · Jul 30, 2026, 11:11 AM
Axogen Participates In Series A Funding Round For Trace Biosciences With Additional Investors Expected To Join; Terms Not DisclosedBenzinga · Jul 29, 2026, 11:14 AM
8-K filing — Axogen, Inc. (AXGN)SEC EDGAR · Jul 29, 2026, 11:11 AM
Axogen Q2 Adj. EPS $0.12 Misses $0.13 Estimate, Sales $69.731M Beat $67.098M EstimateBenzinga · Jul 29, 2026, 11:06 AM
Axogen FY2026 Revenue expected to be at least $279.000M vs $270.882M EstBenzinga · Jul 29, 2026, 11:05 AM